Press coverage about Axovant Sciences (NYSE:AXON) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Axovant Sciences earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.9590454046466 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:

Axovant Sciences (NYSE AXON) traded up 1.64% on Friday, hitting $22.27. The stock had a trading volume of 515,273 shares. Axovant Sciences has a 52-week low of $11.01 and a 52-week high of $26.49. The stock’s 50-day moving average is $22.92 and its 200-day moving average is $19.11. The company’s market cap is $2.37 billion.

Axovant Sciences (NYSE:AXON) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by $0.12. Analysts expect that Axovant Sciences will post ($2.32) earnings per share for the current year.

Several research analysts recently issued reports on the company. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $26.00 target price (up from $20.00) on shares of Axovant Sciences in a research report on Friday, April 14th. Jefferies Group LLC reaffirmed a “buy” rating and set a $31.00 target price on shares of Axovant Sciences in a research report on Tuesday, April 18th. CIBC raised their target price on Axovant Sciences from $30.00 to $33.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 18th. Cowen and Company reaffirmed an “outperform” rating and set a $30.00 target price (up from $22.00) on shares of Axovant Sciences in a research report on Tuesday, June 13th. Finally, BidaskClub raised Axovant Sciences from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company’s stock. Axovant Sciences has an average rating of “Buy” and an average price target of $28.50.

COPYRIGHT VIOLATION NOTICE: “Axovant Sciences (AXON) Receives Daily Media Impact Score of 0.09” was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.